Healthy individuals older than 50 without a history of cancer or cardiovascular disease who took vitamin D supplements daily had a similar risk of developing cancer and major CV events but had 25% reduced odds of cancer mortality, compared with those who received placebo, researchers reported at the American Heart Association's annual meeting and in The New England Journal of Medicine. Another study by the same researchers showed a similar risk of CV events but a 28% lower likelihood of heart attacks among those who took fish oil supplements.
Having concomitant type 2 diabetes and polyvascular disease puts patients with acute coronary syndrome at an increased risk for ischemic events over seven years, compared with those who had just one of the conditions, researchers reported in The Lancet Diabetes & Endocrinology. Based on the IMPROVE-IT trial involving 18,144 patients over 50 years of age, findings showed that type 2 diabetes and polyvascular disease were independently associated with a 60% increase in primary endpoint of myocardial infarction, stroke or cardiovascular death.
Researchers have found that patients who have sickle-cell trait and type 2 diabetes are at a higher risk of developing diabetes-related complications such as diabetic retinopathy, hypertension and decreased renal function, compared with those who only had diabetes, according to a study in Diabetes Care. The study, based on 221 patients, revealed that those with both diabetes and SCT also had higher shear rates of blood viscosity, arterial stiffness and thixotropic index than those with either condition alone or healthy individuals.
A study in JAMA Network Open showed that elderly African American patients with type 2 diabetes and the haptoglobin 1-1 genotype had the lowest mean scores in the Mini-Mental State Examination, a measurement of cognition, and significant declines over 40 months. Researchers conducted a sub-analysis of the ACCORD-MIND study involving 466 patients and found those with the Hp 2-2 genotype also experienced a significant cognitive decline over 40 months.
UK-based Nemaura Medical has developed predictive algorithms to support alarm functionality for its sugarBeat continuous glucose monitoring system. The alarm functionality has accuracies of 98%, 95% and 90% in predicting glucose levels five, 10 and 15 minutes in advance, respectively, the company said.
A residual convolutional neural network that analyzed low-dose FDG-PET images and was developed by researchers at Washington University School of Medicine in St. Louis had elevated mean structural similarity, peak signal-to-noise ratio values and low root mean square error and also yielded similar image quality as full-dose PET images, according to a study in the Journal of Digital Imaging. The findings suggest that the deep learning model may prompt reduced PET imaging costs, but more studies are needed prior to large-scale applications, researchers said.
Researchers at Kyoto University in Japan have transplanted 2.4 million induced pluripotent stem cells to the left brain of a male patient in his 50s with Parkinson's disease. The patient, who will be observed for two years, was stable post-transplant and will receive another implant of 2.4 million cells to the right side of the brain if he doesn't develop complications in the next six months.
Cardinal Health reached a deal to distribute IRE ELiT's Galli Eo gallium-68 generators in an effort to ease a shortage of Ga-68. The generator received FDA approval in September.
Zionexa has entered into an agreement with Columbia University's Kreitchman PET Center to develop and commercialize its PET tracer EstroTep in the US. "The work we are doing here with the team at Columbia is helping us to prepare to submit our product to the FDA for evaluation, and hopefully a future commercial launch in the USA," said Zionexa US CEO Peter Webner.
The Radiological Society of North America Research & Education Foundation and Hitachi Healthcare awarded a $40,000 grant to Dr. David Shultz of the University of Toronto to evaluate PET/MRI with fluoroazomycin arabinoside in determining hypoxic tumors among individuals with localized high-risk sarcoma in an effort to improve sarcoma treatment. Validation of results and characterization of the tumors' biologic features will be done using pimonidazole, a molecular probe for hypoxia.
- Page 1